**Article type:** Original Research

**~~Article title~~**~~: The economic impact of non-communicable diseases among households in South Asia: A Systematic Review~~

Article Title: Out of pocket payment, catastrophic expenditure and impoverishment impact of cardiovascular diseases, diabetes, cancer and chronic respiratory diseases among households in South Asia and their coping strategy: A Systematic Review

**Short title**: Economic impact of NCDs in South Asia

**Authors**: Anupa Rijal1\*, Tara Ballav Adhikari2, Jahangir A. M. Khan3, Gabriele Berg-Beckhoff4

**Authors’ Affiliations:** 1Young Earth, Kathmandu, Nepal 2Nepal Development Society, Chitwan, Nepal 3Liverpool School of Tropical Medicine, Liverpool, United Kingdom; 4Unit for Health Promotion Research, University of Southern Denmark, Denmark

\*Corresponding Author: Anupa Rijal

Email: [anuparijal@gmail.com](mailto:anuparijal@gmail.com)

**Abstract**

**Background**

Out of pocket payment (OOPP), is the major health financing mechanism in South Asia region.With rising burden of non-communicable diseases (NCDs), the region is facing a high financial burden. However, the extent and nature of economic impact caused by treatment and management of NCDs at the household level is yet unknown.

**Method**

We conducted a systematic review using Medline and Embase databases. Only peer-reviewed quantitative studies published between January 2000 to December 2016 assessing OOPP or catastrophic health expenditure or impoverishment or financial coping strategy due to at least one of the four major NCDs - cardiovascular disease(CVD), diabetes, cancer, chronic respiratory disease in South Asia region was included in the review. The review is registered in PROSPERO no: CRD42017059345.

**Results**

A total of 21 studies (of 2693 records identified) met the inclusion criteria. Economic impact was the most frequently studied in CVD and in terms of OOPP. The studies collectively indicated high OOPP, higher likelihood of catastrophic expenditure and impoverishment for inpatient care for these major NCDs which was visible in all income levels. Borrowing and selling of assets were the most common forms of coping strategies adopted and varied inconsistently between urban and rural households. The true extent of the economic impact, however, remains difficult to determine due to methodological heterogeneity regarding outcomes reported and measures employed for calculation of OOPP, catastrophic expenditure, and impoverishment across these four major NCDs and between nations.

**Conclusion**

The economic impact due to treatment and management of CVD, diabetes, cancer and chronic respiratory disease among households in South Asia seems dire. Given the lack of sufficient evidence the review stresses the need for further research in the region to develop evidence-informed nationally tailored prepayment mechanisms covering NCDs to reduce economic vulnerability and standardization of tools measuring the economic impact for generating comparable estimates.

**Keywords:** catastrophic health expenditure, coping strategy, distress financing, impoverishment, non-communicable disease, out of pocket expenditure, poverty, South Asia

**Introduction**

Globally, cardiovascular diseases (CVDs), cancers, chronic respiratory diseases (chronic obstructive pulmonary disease and asthma) and diabetes are leading non-communicable diseases (NCDs) contributing 81% of all NCDs related mortality [1]. NCDs also accounts for 58% of the Disability Adjusted Life Years (DALYs) [1]. With rapid urbanization, sedentary lifestyle [2], increased consumption of unhealthy diets, high alcohol use, and high blood pressure the burden of NCDs have escalated throughout the world in between 1990 and 2010 so as in South Asia [3, 4]. The South Asian countries namely Afghanistan, Bangladesh, Bhutan, Maldives, Nepal, India, Pakistan and Sri Lanka, which are mostly low and middle-income countries with regional Gross Domestic Product (GDP) per capita 1639.7 United States Dollar (USD) and home to a quarter of world population [5]. The region currently bears a high burden of NCDs, and related death is expected to increase by 20% in World Health Organization (WHO)- South-East Asia Region [6]. Studies suggest that the manifestation of CVDs and onset of diabetes is much earlier among South Asians than other ethnicities due to adverse metabolic factors requiring longer-term medication [7].

The growing incidence of NCDs threatens the already weakened health system in South Asia [7, 8]. In the absence of adequate policy direction, diagnostic capacity and effective organizational measures addressing these emerging non-communicable will have a far-reaching impact on health care, both at the individual and institutional level in South Asia. People will be required to pay for expensive treatments and medications out of pocket as most of the countries in the region do not have a functional population-wide insurance system and depends heavily on out of pocket payment (OOPP) [9], which is a derogatory form of health financing. This funding mechanism increases households cost associated with health care and forces households to unprecedented financial catastrophe and impoverishment [10]. WHO defines catastrophic health expenditure is defined as the health expenditure greater than or equal to 40% of a household's effective income remaining after basic subsistence needs have been met (capacity to pay) while if this catastrophic expenditure pushes a household below, or further below, the poverty line it is known as impoverishment [11]. Individuals are not very price sensitive when it comes to treatment and management of disease like NCDs which triggers premature death or disabilities if not treated timely [12]. Hence, households despite their incapability to pay for the health-care services undergo catastrophic payment or adopt different coping behaviors to meet the financial need for hospitalization and health care costs [13]. Whereas, this economic constraint may also lead to the number of untreated cases eventually increasing the burden of NCDs.

When a quarter of world population (where 15.1% of the population live under 1.90 USD per day) [5] living in this region are on the verge of slipping into a vicious cycle of poverty and impoverishment while seeking for healthcare services. This compromises the attainment of the global goal of Universal Health Coverage which is target 8 of goal number 3 of Sustainable Development Goals (SDG) [14]. This goal calls for grand convergence to provide health services relative to need and ensuring financial protection so that health care is within reach of all the population. It also further challenges the attainment of the global action plan for prevention and control of NCDs 2013-2020 which deals with relative reduction of premature NCDs deaths by 25% by 2025 and reducing the contribution of NCDs in financial impoverishment, by identifying the NCDs which needs the urgent intervention at the country level [15].

The current literatures on the discourse of assessing financial burden of NCDs in low and middle income countries by Kankeu et al. [16] Gupta et al.[17] states that studies on estimating costs incurred and impoverishment effect due to NCDs needs to prioritized and robust research should be carried out to produce much needed evidence in the resource constraint settings. Similar need for further research in low and middle income countries was also concluded by Jaspers et al. in a systematic review assessing global impact of NCDs and impoverishment which includes eight studies from India and two from Pakistan both being South Asian countries [18] while evidences from other South Asian countries are lacking. A review of litereature by Saksena et al. discussing on impact of out of pocket payments for non-communicable diseases in developing countries which also included some studies from India suggested that household share substantial share of income for NCDs treatment specially hospitalization related expenditures [19]. However, to the best of the author’s knowledge, no such review exists covering a comprehensive assessment of economic impact caused by specific NCDs exclusively in South Asia region so far. In this study, the term economic impact collectively refers to the OOPP, catastrophic expenditure and impoverishment impact due to management and treatment of CVDs, diabetes, chronic respiratory diseases and cancers. Hence, given the gap in the literature, and to update on existing evidence of economic impact by NCDs the current study will systematically review the existing evidence on the OOPP, catastrophic and impoverishment effect of NCDs along with individual and households coping strategies to these financial constraints in South Asia.

**Methods**

In order to conduct a systematic review assessing the economic impact of NCDs and impoverishment among households in South Asia region, the Preferred Reporting Items for Systematic Reviews and Meta-analyses statementwas used as a reporting guideline for this review. The PROSPERO registration number for the review is CRD42017059345.

**Search Strategy**

We systematically searched two electronic databases accessed through Ovid: Medline and EMBASE by using database tailored search strategy. The search strategy was adapted from the similar systematic review conducted by Jaspers et. al.[18] and was based on PECO (Population, Exposure Comparison, and Outcome) framework covering the objectives of this review and appropriate Subject Headings was used and was searched in titles, abstracts, topics, and keywords depending on the database. The latest search was conducted on 17th February 2017. Additionally, snowballing technique was applied for the manual search of studies from the list of references and citations of retrieved articles to identify studies not found in the database search. The complete search strategy is available as supporting document. **(Supplementary file 1)**

**Inclusion Criteria**

Quantitative studies conducted in at least one of the following countries: Nepal, India, Pakistan, Sri Lanka, Bhutan, Bangladesh, Maldives among any gender (male or female) in any age group including at least one of the four major NCDs: CVDs, type II diabetes, chronic respiratory diseases (chronic obstructive pulmonary disease and asthma) and cancers examining at least one of the measures of economic consequences caused by NCDs at households were considered in the review. In this systematic review we only included peer-reviewed English research articles published between January 2000 to December 2016.

Given the existence of different types of cancers and our limited resources, the detailed search strategy in the review majorly focused on cancers with leading DALYs rate among South Asian male (Lung cancer and Oral Cancer) and female (Breast cancer and Cervical cancer) [20]. However, studies assessing economic impact of these specific cancer or cancers/neoplasm in general were both included in the review. The economic measures included in the review were direct costs, indirect costs, expenditure on medicine, transport, out of pocket expenditure, financial hardship, catastrophic health expenditure, impoverishment, individual or household cost, poverty line, or coping strategy for NCDs related financial burden.

**Exclusion Criteria**

Studies though satisfying the inclusion criteria but with an inadequate assessment of measures of outcome, and or of unsatisfactory quality and unfeasible for data extraction were not considered for the review. Studies from Afghanistan was not considered for the review as it became the member of South Asia only since 2008.

**Study selection**

Studies were initially identified based on title and abstracts, and when abstracts were not relevant or did not provide sufficient information, the full-text articles were retrieved and screened against inclusion and exclusion criteria by first and second author independently. Any disagreement between two reviewers was resolved through consensus and consultation of the third reviewer.

**Data extraction from selected articles**

All the references form both the databases were exported to EndNote X7.7.1, and duplicate studies were removed. Three different data collection forms were made to collect relevant information from the included articles. The first form included information about the characteristics of studies. The second data extraction form was used for category wise assessing quality of the study based on Newcastle– Ottawa Quality Assessment Scale and final quality score for each study was assigned [18]. The third data extraction form contained the details about the assessment of the outcome of interest.

Local currencies were converted to US dollars (USD) to enhance comparability between the eligible studies. We used country specific Purchasing Power Parity conversion rate provided by World Bank data [21]. The conversion rate of the publication year of the study was used. Furthermore, all USD were converted to dollars of 2016 using the consumer price index conversion factors [22].

**Risk of bias analysis**

Newcastle–Ottawa Quality Assessment Scale (NOS) adapted for the cross-sectional and descriptive study was used in the review [23]. The NOS scale assesses the quality of the articles in three domains of selection, comparability, and exposure and is based on ‘star system.’ The selection and exposure category include four and three items respectively and can be provided one star each while comparability with one item can be provided two stars. Hence the NOS scale can have maximum nine stars for the highest quality. A score was tallied by adding up the stars. A study was categorized as being of low risk of bias or highest quality if a total of 8 to 9 stars were allocated, medium risk of bias if 6 to 7 stars were allocated and of high risk or poor quality if the total score awarded was ≤ 5 stars.

**Data analysis and synthesis**

Disease-specific data extracted were synthesized in groups and inferences were made. Given the heterogeneity regarding methods and outcomes addressed, the results were not combined across studies, and no summary measures were calculated.

**Result**

From 2,693 references initially screened 22 studies met the inclusion criteria and had been included in the review. (Fig 1)

Figure 1. PRISMA Flow-chart for systematic review of studies

311 duplicates removed

Records identified through database searching (n=2684)

Additional records identified through other sources

(n = 9)

Records after duplicates removed  
(n = 2382)

Records screened  
(n = 2382)

Records excluded based on title and abstract  
(n=2336)

Records given full text detailed assessment   
(n=46)

Full Text articles excluded  
(n=25)

1. No or non- specified NCD (n=14)
2. Outcome not specified as interest of the review (n=4)
3. Not South Asia (n=1)
4. Other (n=4)

Studies included

(n=22)

**Characteristics of the study reviewed**

**Table 1** shows characteristics of 21 studies included in the review out of which 14 studies were solely based in India. There were no studies identified from Maldives and Bhutan regarding economic impact, related impoverishment and coping strategy due to NCDs. Studies varied from 50 to 200000 observations. Fifteen studies included individuals as sample unit while eight studies used household as unit of analysis and all these studies had sample size >1500 [24-31] [24, 25, 29-34].

Majority of the studies were cross-sectional in nature. Only three studies followed up to six months after discharge of patients and collected information on economic impact [35-37].

Fifteen studies used random sampling while 9 studies were based on purposive sampling for identifying the respondents as shown in **Table 1**. The purposive sampling was usually done in purposively identified hospitals or health care center setting among patients visiting health centers or parents/closet patient party of either hospitalized patients or those who survived hospitalization/surgery except for one where purposive program area was first selected and household survey was done.

For assessment of NCDs, majority of the studies identified CVDs, diabetes, chronic respiratory diseases and cancers based on clinically confirmed/diagnosed record, inpatient/outpatient cases, hospitalization record, or those who survived hospitalization/surgery. Five studies in the review identified NCDs based on self-reporting of symptoms or ailments and cross matching with the ICD-9 [25]or with categorization of disease based on symptoms based on previous studies or WHO classification [26, 30, 38] while one study self-reported symptoms were first cross matched with pre-determined stroke definition and these positive cases were then confirmed neurologist [39]. Likewise, two studies used both clinically confirmed cases wherever information on clinical diagnosis was available if not self-reported symptoms cross matched with NCD pre-determined categorization was used [24, 31] while one study was entirely based on self-reporting of the conditions from respondents [40] .

In all the studies included in the review, the measure of outcome, i.e., an economic impact of NCD was based on self-reported information on household expenditure, cost, financial burden, etc. at the household or individual level. Two studies applied Propensity Score matching to assess the economic burden of NCD by comparing the means between the NCD affected households and matched control household using a t-test [24, 34]. Except one, all other NCDs were studied the among adult population 18 years and above. CVD was the most frequently reported NCDs in the studies. Overall, among the 21 studies included in the review, CVD was most commonly studied NCD (14 studies) followed by diabetes (9 studies), cancer (6 studies) and lastly chronic respiratory disease (5 studies). Except one study mentioning breast cancer, no other cancer articles included in the review have specified on the type of cancer assessed in the study and its economic impact on household [41].

Majority of the studies (12 studies) were of poor quality with scoring ≤ 5 stars, 7 were of moderate quality and only 3 studies were of high quality [24, 28, 29]. The median quality score was 5 out of 9 (minimum 1, maximum 8) with an interquartile range of 3. **(****Supplementary file 2)**

## Measurement of economic impact

The measurement of economic impact caused by NCDs was too heterogeneous. The most common reported economic impact was OOPP followed by catastrophic health expenditure while very few studies dealt with impoverishment, financial hardship, and coping strategy.

**OOPP**

The common measure of OOPP was expenditure for per hospital stay or inpatient care or hospitalization cost per household member [24, 25, 34, 35, 38] while cost subdivided in terms of indirect cost, direct cost, non-medical cost or was calculated altogether [42, 43]. OOPP as the proportion of total household spending [34, 38] or perceived financial hardship by caretakers was also studied [41].

**Catastrophic health expenditure**

Catastrophic health expenditure has been reported to varying degree of threshold and denominators. Among the studies included in the review, two studies included household’s ‘capacity to pay’ as denominator at 40% level threshold [24, 42] while Huffmann et al. used household non-food expenditure [44]. Likewise, studies also included annual baseline income and total household expenditure as denominator at 30% and 10% threshold respectively [31, 35]. Only one study measured the intensity of catastrophic payment by assessing the mean positive overshoot which uses only those households that have experienced catastrophic health expenditure in actual as the denominator [31].

**Impoverishment**

Out of 22 studies, only three studies dealt with impoverishment effect of out of pocket spending on health care for the NCDs of interest [24-26]. Impoverishment was expressed in terms of percentage of household healthcare spending exceeding purchasing power parity represented in terms of either relative poverty line USD 0.88 (for Bangladesh) [26] and absolute poverty line USD 1.25 per day per person [24]. Hamid et al. further represented medical impoverishment in terms of poverty impact, poverty gap and normalized poverty gap [26]. While Engelgeu et al expressed it in terms of odds of undergoing impoverishment for household with CVDs and cancer as compared to household with communicable disease and used relative poverty line estimates for different states and regions of India [25].

**Coping Strategy**

Only13 studies that dealt with the coping strategy adopted by individuals and households to meet OOPP for NCDs related treatment. Studies reported either the percentage or risk of using alternate financial measures like borrowing, selling of assets, loans, etc. also denoted as distress financing [30, 33].

**Summary of the economic impact of NCDs in South Asia**

Overall**,** this systematic review further highlighted that major non-communicable diseases; cardiovascular disease, cancer, diabetes and chronic respiratory disease impart economic impact among households in South Asia however the extent and magnitude of the impact is still inconclusive. Nonetheless, the studies in the review uniformly showed OOPP, catastrophic health expenditure and impoverishment among households with NCDs was higher as compared to household without NCDs and the economic impact was visible in different income levels. Among the studies dealing with coping strategy to meet the financial costs of inpatient care for these NCDs borrowing and selling of assets were most commonly exhibited coping strategy by South Asian household. These coping behaviors however differed inconsistently based on place of residence either rural or urban.

**Economic impact of cardiovascular diseases**

In table 2, studies showed that out of pocket health spending per person was high among angina and CVDs affected household as compared to control and matched household respectively [24, 28]. The regional proportion of households suffering from financial catastrophe for CVD-related treatment ranged from 20% to 90% depending on the chosen income threshold taken in the studies. The inter-country study among Nepal, Bangladesh, India, and Sri Lanka revealed that household in Bangladesh had the highest prevalence of catastrophic health expenditure (as household’s capacity to pay at 40% cut off point) and impoverishment due to Angina treatment (39.4% and 12.6% respectively). Among Nepalese household, a significant proportion had to undergo borrowing or selling off assets (57.62%) to finance health expenditure. However, much higher (84%) catastrophic spending was reported for Acute Coronary Syndrome (ACS) treatment in India at the same threshold [42]. Studies reflected that the financial hardship and catastrophic health expenditure led by CVDs treatment was visible in both rich and poor households. More than a quarter (26.3%) of high income Indian households had decreased income due to treatment for CVDs [44]. Likewise, the wealthiest household with heart disease from Nepal were 2.36 times more likely to undergo catastrophic health expenditure as compared to household without heart disease [31]. Moreover, borrowing, contribution from friends, sell off assets to meet OOPP for CVDs treatment was found to be concentrated in rural areas in India. Raj et. al showed that such coping strategies were prominent even after completion of surgery for congenital heart surgery as more than half (52.1%) of households in India reported borrowing money even after 6 months of discharge from congenital heart surgery to take care of the child and pay the loan made earlier for the treatment [37].

**(Table 2)**

**Economic impact of diabetes**

Table 3 demonstrates the OOPP for diabetes in India and Pakistan, impoverishing effect in Bangladesh and catastrophic health expenditure led by diabetes treatment in Nepal. Inpatient diabetes care covered 17% of the household expenditure and income respectively in India [38, 45]. The cost of diabetic treatment varied significantly between private and public hospitals (6602.13 USD vs. 1320.43 USD) in India within a year [45]. Khuwaja et al. reported slightly higher direct cost for diabetes care in India as compared to Pakistan [46, 47]. Households with diabetes posed more than twice the risk of spending more than 10% of total expenditure on health than households without diabetes, and the mean positive overshoot was 10.2% [31]. Moreover, 5.25% of households fell into poverty due to payment for diabetes care in Bangladesh, and the poor household falls short of poverty line by 1.1 cents [26]. Similar to financing for CVD rural households continued to adopt distress financing as compared to the urban household. Selling off assets and assistance from family or friends were respectively 13 times and 21 times more common in diabetes affected households as compared to households without diabetes [33].

**(Table 3)**

**Economic impact of cancer**

Table 4 shows the studies on the economic impact of cancer from India, Bangladesh, and Pakistan. The mean inpatient expenditure in cancer affected household was almost 5 times higher than the matched control household in India (326.93 USD vs 66.42 USD) [29]. While another study in India reported very high cost of treatment alone of around USD 2543 [48] and the cost of hospitalization was reported to be more than double in 8 years span [25]. Seven out of ten households in Pakistan perceived breast cancer the imposed financial burden, and the cost of treatment was unmanageable for breast cancer [41]. Studies reported significant impoverishment induced by cancer treatment among households in Bangladesh and India [25, 26]. In Bangladesh, the impoverishing effect was much more pronounced for the most impoverished family as they further fall into poverty by 8% due to cancer treatment. This is the highest reported normalized poverty gap as compared to CVD and Diabetes by the same study. Similar to other NCDs, households borrowed or sold the asset to finance for inpatient care as compared to matched or control households [33].

**(Table 4)**

**Economic impact of chronic respiratory disease**

Table 5 summarizes the studies conducted in India, Bangladesh, and Nepal on OOPP, catastrophic health expenditure, impoverishment and financial coping strategy adopted for treatment of chronic respiratory disease. The average out of pocket expenditures per visit for non-domiciliary treatment of COPD was higher for urban households in Bangladesh than the rural ones (41.98 USD vs 4.38 USD) [49]. Almost 6% of the Bangladesh household fell into poverty due to payment for asthma health care services and the intensity of medical impoverishment was increased by 2% for poorest household. The risk of household undergoing catastrophic health expenditure was higher in the poorest household as compared to wealthiest quintile, RR 2.09(1.39 at 95% CI) in Nepal. Around three-quarters of Bangladeshi household were at risk of implementing one of the coping strategies like borrowing and selling off assets to finance for Asthma treatment [30], and this risk was higher among urban households [49]. Among Indian households the OOPP per inpatient treatment in private and public hospital for bronchial asthma was increased tremendously between 1995 and 2004; 195.80 USD and 522.13 USD respectively [25].

**(Table 5)**

**Discussion**

This systematic review summarizes 22 studies assessing the economic impact in terms of OOPP, catastrophic health expenditure, impoverishment caused by management and treatment of CVDs, diabetes, cancer, chronic respiratory diseases among households in South Asia and their financial coping strategy. However, no single conclusion could be made regarding NCDs induced out of pocket expenditure and its economic impact in the region because of significant methodological heterogeneity among studies and variation in reporting of findings.

Before discussing the major findings of this systematic review, it is important to discuss on the methodological variations the studies have presented in measuring OOPP, catastrophic health expenditure, impoverishment across South Asian countries. The methodological differences occurred in terms of measurement of out of pocket i.e. inclusion of direct cost, indirect cost, non-medical cost and variance in recall period. Though majority of the studies were based on random samples the cost associated with NCDs was self-reported in all cases. These self-reported costs associated with NCDs even for random samples are likely to over report the expenses specially in lack of comparative group [16, 50]. The recall period in the studies varied from a few days to 12 months. Long recall is subjected to misreporting due to respondent inability to remember exact out of pocket expenditures while short recall period do not capture the actual expenses and are likely to exaggerate or over report the expenses [51, 52].

Currently, WHO uses the incidence of catastrophic health expenditures and the incidence of impoverishment due to out-of-pocket health payments as indicators to monitor level of financial protection for Universal Health Coverage [53]. However, in this review studies majority of studies reported OOPP due to NCDs and only few studies reported incidence of catastrophic health expenditure and even fewer (only three) studies reported incidence of impoverishment. Hence restressing the gap of availability of data regarding financial protection in low and middle income countries [53] including the South Asian region. Likewise, for measurement of catastrophic health expenditure studies used different thresholds ranging from 10% and 40% spent as health expenditure of total household consumption expenditure or total household non-food consumption expenditure while one study used “mean catastrophic positive overshoot” i.e. the degree by which the average out of pocket expenditure by households that have experienced catastrophe has exceeded the given catastrophic threshold [51].Thus, hindering the comparability between studies and diseases. Similarly, approaches to assess impoverishment among the studies still differed widely. Studies either used absolute poverty line or locally derived poverty line while only one study assessed poverty gap (i.e.households pushed further into poverty). Moreover, the OOPP, catastrophic health expenditure and impoverishment are out-product of political and societal settings: availability and access to health services, risk pooling and health financing mechanism and poverty levels in each country. Hence results should be cautiously interpreted on these socio-political paradigm [51, 54]. Thus, this systematic review highlights the need for standardized definitions, thresholds for assessing OOPP and its impact, studies going beyond the measurement of OOPP alone and measuring the incidence of catastrophic health expenditure and impoverishment and preparing tools that are not sensitive to political and societal factors is must to make a cross-country and fair comparisons.

Additionally, most of the studies were cross sectional in nature hence failed to answer whether the catastrophic and impoverishing effects observed, and coping strategy adopted occurred in a unit of time or is the aggregation of such impacts over a period for a household. The duration over which a household feels catastrophic or impoverishing effects may be more important than the incidence of the results in the population itself [55] specially in case of NCDs which require lifelong expenses for medication and care which was not reported in any of the studies in the review. Moreover, majority of the studies in the review was of poor quality mainly due to inadequately defined NCDs, lack of reference group/comparator and cross section nature of the study. **(Supplementary file 2)** Out of pocket expense for NCDs in lack of reference group or comparator gives very little information. Hence these findings stress the need of robust research on NCDs and its economic impact with optimal methodological design along with appropriate reference group and comparators group to facilitate the production of meaningful and comparable national and regional estimates.

Despite the methodological differences, the review has been able to highlight some important issues on economic impact due to CVDs, diabetes, chronic respiratory disease and cancer among households in South Asian region. Firstly, one of the peculiar findings of the review was majority of the studies originated from India and only few were based on other member states of South Asia. This lack of evidence may be subjected to the fact that NCDs are emerging public health problem in South Asia region where the health system is predominantly focused on tackling the challenges caused by infectious disease. However, this systematic review identified a total of 13 new studies from India, Nepal, Pakistan and Bangladesh which were previously not mentioned in systematic review conducted at global level [18]. Unlike the findings from the global systematic review, this systematic review has been able to highlight that there was prominent lack of studies on economic impact of specific type of cancer and COPD in the South Asian region. One of the explanations for this could be insufficient population-based cancer registry in the region to draw cancer-specific data [56]. It is commonsensical that disregarding different types, stages and trajectories of cancer will lead to underreporting and underestimation of the financial burden caused by cancer [57, 58]. Similar lack of studies assessing economic impact of COPD, a major DALY contributor in South Asia may be because COPD is ignored as cough or smoker cough and leading to reduced number of individual seeking health service but potentially increase costs due to ill-diagnosis or later diagnosis. As the epidemiological burden of COPD increases in the region, it is expected that household will undergo higher out of pocket payment and its subsequent impact. Hence future studies on economic impact of COPD in South Asia could provide us with important information to formulate evidence based tailored policy to address the economical and epidemiological burden of COPD in the region.

Secondly, the review reconfirmed that households suffering from NCDs had higher out of pocket expenditure, catastrophic health expenditures and were more likely to undergo impoverishment compared to its counterparts which concurs with similar literature review conducted in low and middle income countries [59, 60]. A literature review on financial burden on NCDs in resource constraint setting showed that comorbidities associated with NCDs and the cost of medication occupied the largest proportion in direct cost associated with treatment of NCDs [16, 61].

Thirdly, the review also pointed out that the current health services for these NCDs are unaffordable to already poverty-stricken population of the region. For instance, among the studies in the review, the highest out of pocket direct cost 11,989 USD was reported for congenital heart surgery for 0 to 18 years children [37] in India where almost a quarter of the population live below 2 USD per day [5]. Similar disproportionate risk of catastrophic expenditure among uninsured and poor household was also seen in case of chronic respiratory disease [26, 31] and CVDs [25, 35] in the review. Surprisingly, the consequential effect was also visible in the high-income household [31, 44]. For instance, the households with heart disease from wealthiest quintile in Nepal had slightly increased risk of catastrophic health expenditure than the poorest household. This does not necessarily a mean poorest household suffer less from CVDs than richest household, this may also signify that poor household does not have financial ability to seek care, so they avoid health service hence lesser expenditure altogether. However, households or individuals not seeking health care for NCDs and its financial implications was overlooked and not discussed in any of the studies included in the review.

Fourthly, this systematic review also showed that borrowing and selling off assets as the most common coping strategy adopted by households in the region for all major NCDs in this review. A study done among African nations showed similar results for paying their inpatient health costs [62]. However, the proportion of households adopting coping strategy varied inconsistently between rural or urban place of residence [27, 63]. On the one hand, this difference in coping behavior can be attributed to poor economic conditions where only well-endowed households can pay for their health care services and people from the rural area must find alternative measures to pay for their health [64]. Whereas the high percentage of urban distress financing reiterates that coping behavior is strongly correlated with the availability of social capital, valuable assets, possibility of getting a loan which is higher among affluent group living in a urban household [62, 65]. High dependence on coping strategy at present will reduce the ability of families to deal with unprecedented health shocks in the future and increase debt in a poor household.[60] Furthermore, borrowing or incurring loan or contributions from family and friends may also depend on the individual needing health care. The healthcare need of female and elderly are not prioritized in the patriarchal society as such of South Asia, hence reduced coping measures or not seeking health care at all [25]. This intersectionality of gender and age group from the perspectives of health financing and coping strategies among households has not been studied yet in low and middle-income countries [27].

Thus, given the lack of risk pooling mechanism and heavy dependence on paying out of pocket for health financing rapid privatization of health services in the region [8], preference of private health facilities over public facilities for quality of care and diagnostics in case of NCDs [66], it is very likely that seeking health care services for NCDs will push households to medical poverty and will create the intergenerational cycle of poverty and poor health [8, 54]. If the current situation prevails it will also undermine the goal of attainment of Universal Health Coverage- appropriate care at affordable cost in the South Asian region.There has been some initiatives from South Asian countries to bring forward population-based insurance scheme [67-69], WHO Package of Essential Non-communicable program [70, 71], however challenges remain. Recent evidence suggest that population covered under health insurance program or national schemes is not an ultimate solution for financial protection [72, 73]. In order to reduce catastrophic health expenditure and impoverishment mechanisms where large share of health expenditure is prepaid through tax or mandatory payment system is of utmost importance [72, 73]. This is however profoundly absent in the South Asian region. Thus, in such a scenario the appropriate mix of preventive and promotive approaches to modify NCDs risk factors and reduce the epidemiological burden hence reducing the cost associated with its treatment and management in the long run could be beneficial.

One of the biggest strength of this systematic review was the comprehensive nature of search strategy applied and use of Newcastle –Ottawa Quality Assessment Scale to assess the quality of non-randomized studies including case-control and cohort studies [74]. This has been previously tested in a systematic review done to evaluate the global impact of NCDs on households and impoverishment with appropriate adaptation as per the objectives of this systematic review [18]. Another significant strength of the review is the conversion of local currency to US Dollars. The Purchasing Power Parity conversion rate is the number of units of a country's currency required to buy the same amounts of goods and services in the domestic market as U.S. dollar would buy in the United States [75]. This conversion factor takes account of the GDP of the country hence giving superior comparability than exchange rate. Moreover, all USD converted to dollars in 2016 through consumer price index conversion takes inflation rate in consideration hence inferences on out of pocket payment are comparable and reliable.

However, this review is not devoid of limitations. The main limitation of our review is the use of only two databases, Medline and Embase for searching articles though they cover a large range of peer reviewed articles published from 1946 to till date on biomedicine and health. Hence may have missed related articles from other databases. In order to minimize this limitation, we also conducted snowballing of references to ensure no potentially relevant studies were left out. But we acknowledge that relevant publications in local languages and Ministerial surveys and reports regarding this issue which could have been of vital importance has not been included in the review. Another major limitation of this review occurred in the selection of cancer studies. We only included four cancers with leading DALYs rates among men and women in South Asian region in the search strategy for detail exploration. However, we widened out our inclusion criteria so that studies assessing economic impact but failing to mention non-specific cancers/neoplasms was also included in the review so that we do not miss out important information on cancer led economic impact. Lastly, our review does not take in account of comorbidities associated with NCDs which have found to play a significant role in increasing disease burden and cost of treatment.

**Conclusion**

Our review suggests that the economic impact of CVDs, diabetes, cancer and chronic respiratory diseases among households in South Asia seems dire. Out of pocket payment, catastrophic payment and impoverishment are significantly high in households with NCDs and affects households in all income levels. Borrowing and selling of assets were most common coping behavior exhibited by South Asian household and differed inconsistently with rural and urban residence. However, the studies on economic impact associated with NCDs specially assessing catastrophic health expenditure and impoverishment are inadequate in the region and the gap of evidence for COPD and specific cancer is even higher. Thus, the review highlights the need for robust research on economic impact of NCDs so that evidence-informed nationally tailored prepayment mechanisms covering NCDs can be developed. The review also calls for standardization of tools measuring out of pocket payment and associated catastrophic and impoverishing effect in South Asia which will facilitate the production of meaningful and comparable national and regional estimates.

**Abbreviations**

**COPD** Chronic Obstructive Pulmonary Diseases

**CVDs** Cardiovascular Diseases

**DALYs** Daily Adjusted Life Years

**GDP** Gross Development Product

**NCDs** Non-Communicable Diseases

**OOPP** Out of Pocket Payment

**USD**  United States Dollar

**WHO**  World Health Organization

**Authors Contributions**

AR conceived the study objectives and designed the methodology. AR and TBA screened and retrieved articles from databases. AR did the data extraction. AR prepared a first draft of this paper, which was subsequently reviewed in multiple rounds by GBB, TBA, JAMK and AR. GBB provided overall supervision of the work with contribution in study design, and revision of the manuscript. All authors approved the final version of the submitted manuscript. AR is guarantor.

**Funding**

Nil

**Competing interest**

None declared

Uncategorized References

1. Global Health Estimates 2015. Deaths by Cause, Age, Sex, by Country and by Region, 2000-2015 Geneva: World Health Organization, 2016.

2. Richards NC, Gouda HN, Durham J, Rampatige R, Rodney A, Whittaker M. Disability, noncommunicable disease and health information. Bulletin of the World Health Organization. 2016;94:230-2. doi: <http://dx.doi.org/10.2471/BLT.15.156869>.

3. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224-60.

4. Lee I-M, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT. Impact of Physical Inactivity on the World’s Major Non-Communicable Diseases. Lancet. 2012;380(9838):219-29. doi: 10.1016/S0140-6736(12)61031-9.

5. The World Bank. Poverty and Equity 2017. Available from: <http://povertydata.worldbank.org/poverty/region/SAS>.

6. World Health Organization [WHO]. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization, 2011.

7. Misra A, Jafar T. Diabetes, cardiovascular disease, and chronic kidney disease in South Asia: current status and future directions. BMJ. 2017;357:j1420. doi: <http://dx.doi.org/10.1136/bmj.j1420>.

8. Sengupta A. The rise of private medicine in South Asia. BMJ. 2017;357:j1482. doi: <http://dx.doi.org/10.1136/bmj.j1482>.

9. O’Donnell O, Doorslaer Ev, Rannan-Eliya RP, Somanathan A, Adhikari SR, Akkazieva B, et al. Who pays for healthcare in Asia. Journal of Health Economics. 2008;27:460-75.

10. Van Doorslaer E, O'Donnell O, Rannan-Eliya RP, Somanathan A, Adhikari SR, Akkazieva B, et al. Paying out-of-pocket for health care in Asia: Catastrophic and poverty impact. Rotterdam and IPS, Colombo Erasmus University, 2005 May. Report No.: 2.

11. Xu K, Evans DB, Carrin G, Aguilar-Rivera AM. Designing health financing systems to reduce catastrophic health expenditure. Geneva: World Health Organization, 2005 Contract No.: WHO/EIP/HSF/PB/05.02.

12. World Health Organization [WHO]. Tracking universal health coverage: first global monitoring report. Geneva: World Health Organization, 2015 July 21 Report No.

13. Chuma J, Gilson L, Molyneux C. Treatment‐seeking behaviour, cost burdens and coping strategies among rural and urban households in Coastal Kenya: an equity analysis. Tropical Medicine & International Health. 2007;12(5):673-86.

14. World Health Organization [WHO]. Universal health coverage (UHC) 2016 [updated December 2016]. Available from: <http://www.who.int/mediacentre/factsheets/fs395/en/>.

15. Beaglehole R, Bonita R, Ezzati M, Alleyne G, Dain K, Kishore SP, et al. NCD Countdown 2025: accountability for the 25× 25 NCD mortality reduction target. The Lancet. 2014;384(9938):105-7.

16. Kankeu HT, Saksena P, Xu K, Evans DB. The financial burden from non-communicable diseases in low- and middle-income countries: a literature review. Health Research Policy and Systems. 2013;11(31).

17. Gupta I, Roy A. Economic Studies on Non-Communicable Diseases and Injuries in India: A Systematic Review. Applied Health Economics and Health Policy. 2018;16(3):303-15.

18. Jaspers L, Colpani V, Chaker L, Lee SJvd, Muka T, Imo D, et al. The global impact of non-communicable diseases on households and impoverishment: a systematic review. Eur J Epidemiol. 2015;30(3):163-88. doi: 10.1007/s10654-014-9983-3.

19. Saksena P, Xu K, Evans DB. Impact of out-ofpocket payments for treatment of noncommunicable diseases in developing countries: A review of literature. Geneva: World Health Organization [WHO], Department of Health Systems Financing; 2011.

20. Institute for Health Metrics and Evaluation, Human Development Network, The World Bank. The Global Burden of Disease: Generating Evidence, Guiding Policy-South Asia Regional Edition Seattle, WA: IHME, 2013.

21. PPP conversion factor, GDP (LCU per international $) [Internet]. 2017 [cited 13 Feb 2017]. Available from: <https://data.worldbank.org/indicator/PA.NUS.PPP>.

22. Consumer Price Index (CPI) conversion factors for years 1774 to estimated 2027 to convert to dollars of 2016 [Internet]. [cited 12 Feb 2017]. Available from: <http://liberalarts.oregonstate.edu/sites/liberalarts.oregonstate.edu/files/polisci/faculty-research/sahr/inflation-conversion/pdf/cv2016.pdf>.

23. Wells GA , Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Available from: <http://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf>.

24. Alam K, Mahal A. The economic burden of angina on households in South Asia. BMC Public Health. 2013;14:179. PubMed PMID: 24548585.

25. Engelgau MM, Karan A, Mahal A. The economic impact of non-communicable diseases on households in India. Globalization and Health. 2012;8(9).

26. Hamid SA, Ahsan SM, Begum A. Disease-specific impoverishment impact of out-of-pocket payments for health care: evidence from rural Bangladesh. Applied Health Economics & Health Policy. 2014;12(4):421-33. PubMed PMID: 24854546.

27. Joe W. Distressed financing of household out-of-pocket health care payments in India: incidence and correlates. Health Policy & Planning. 2015;30(6):728-41. PubMed PMID: 24966294.

28. Karan A, Engelgau M, Mahal A. The household-level economic burden of heart disease in India. Tropical Medicine & International Health. 2014;19(5):581-91. PubMed PMID: 24612174.

29. Mahal A, Karan A, Fan VY, Engelgau M. The economic burden of cancers on indian households. PLoS ONE. 2013;8(8):e71853. doi: 10.1371/journal.pone.0071853.

30. Rahman MM, Gilmour S, Saito E, Sultana P, Shibuya K. Self-reported illness and household strategies for coping with health-care payments in Bangladesh. Bulletin of the World Health Organization. 2013;91(6):449-58.

31. Saito E, Gilmour S, Rahman MM, Gautam GS, Shrestha PK, Shibuya K. Catastrophic household expenditure on health in Nepal: A cross-sectional survey. Bulletin of the World Health Organization. 2014;92(10):760-7.

32. Hamid SA, Ahsan SM, Begum A. Disease-specific impoverishment impact of out-of-pocket payments for health care: evidence from rural Bangladesh. Applied Health Economics & Health Policy. 12(4):421-33. PubMed PMID: 24854546.

33. Joe W. Distressed financing of household out-of-pocket health care payments in India: incidence and correlates. Health Policy & Planning. 30(6):728-41. PubMed PMID: 24966294.

34. Karan A, Engelgau M, Mahal A. The household-level economic burden of heart disease in India. Tropical Medicine & International Health. 19(5):581-91. PubMed PMID: 24612174.

35. Jan S, Lee SWL, Sawhney JPS, Ong TK, Chin CT, Kim HS, et al. Catastrophic health expenditure on acute coronary events in Asia: A prospective study. Bulletin of the World Health Organization. 2016;94(3):193-200.

36. Kwatra G, Kaur P, Toor G, Badyal DK, Kaur R, Singh Y, et al. Cost of stroke from a tertiary center in northwest India. Neurology India. 2013;61(6):627-32. PubMed PMID: 24441331.

37. Raj M, Paul M, Sudhakar A, Varghese AA, Haridas AC, Kabali C, et al. Micro-economic impact of congenital heart surgery: results of a prospective study from a limited-resource setting. PLoS ONE [Electronic Resource]. 2015;10(6):e0131348. PubMed PMID: 26110639.

38. Rao KD, Bhatnagar A, Murphy A. Socio-economic inequalities in the financing of cardiovascular & diabetes inpatient treatment in India. Indian J Med Res. 2011;133(1):57-63.

39. Das S, Hazra A, Ray BK, Ghosal M, Banerjee TK, Roy T, et al. Burden among stroke caregivers: Results of a community-based study from Kolkata, India. Stroke. 2010;41(12):2965-8.

40. Joshi A, Mohan K, Grin G, Perin DM. Burden of healthcare utilization and out-of-pocket costs among individuals with NCDs in an Indian setting. Journal of community health. 2013;38(2):320-7.

41. Zaidi AA, Ansari TZ, Khan A. The financial burden of cancer: Estimates from patients undergoing cancer care in a tertiary care hospital. International Journal for Equity in Health. 2012;11 (1) (no pagination)(60).

42. Daivadanam M, Thankappan KR, Sarma PS, Harikrishnan S. Catastrophic health expenditure & coping strategies associated with acute coronary syndrome in Kerala, India. Indian J Med Res. 2012;136(4):585-92.

43. Kwatra G, Kaur P, Toor G, Badyal DK, Kaur R, Singh Y, et al. Cost of stroke from a tertiary center in northwest India. Neurology India. 61(6):627-32. PubMed PMID: 24441331.

44. Huffman MD, Rao KD, Pichon-Riviere A, Zhao D, Harikrishnan S, Ramaiya K, et al. A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries. PLoS ONE [Electronic Resource]. 2011;6(6):e20821. PubMed PMID: 21695127.

45. Shobhana R, Rao PR, Lavanya A, Williams R, Vijay V, Ramachandran A. Expenditure on health care incurred by diabetic subjects in a developing country — a study from southern India. Diabetes Research and Clinical Practice. 2000;48:37-42.

46. Grover S, Avasthi A, bhansali A, Chakrabarti S, Kulhara P. Cost of ambulatory care of diabetes mellitus: a study from North India. Postgrad Med J. 2005;81:391-5.

47. Khowaja LA, Khuwaja AK, Cosgrove P. Cost of diabetes care in out-patient clinic of Karachi, Pakistan. BMC Health Services Research. 2007;7(189).

48. Nair KS, Raj S, Tiwari VK, Piang LK. Cost of treatment for cancer: experiences of patients in public hospitals in India. Asian Pacific Journal of Cancer Prevention. 2013;14(9):5049-54.

49. Uddin MJ, Alam N, Koehlmoos TP, Sarma H, Chowdhury MA, Alam DS, et al. Consequences of hypertension and chronic obstructive pulmonary disease, healthcare-seeking behaviors of patients, and responses of the health system: a population-based cross-sectional study in Bangladesh.[Erratum appears in BMC Public Health. 2014;14:823 Note: Koehlmoos, Tracey P [added]]. BMC Public Health. 14:547. PubMed PMID: 24888580.

50. Murray CJ, Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S. Comparative quantification of health risks conceptual framework and methodological issues. Popul Health Metrics. 2003;1(1).

51. Saksena P, Hsu J, Evans DB. Financial risk protection and universal health coverage: evidence and measurement challenges. PLoS Med. 2014;11(9):e1001701.

52. Lu C, Chin B, Li G, Murray CJ. Limitations of methods for measurig out-of pocket and catastrophic private health expenditures. Bulletin of the World Health Organization. 2009;87:238-44. doi: 10.2471/BLT.08.054379.

53. Boerma T, Eozenou P, Evans D, Evans T, Kieny M-P, Wagstaff A. Monitoring Progress towards Universal Health Coverage at Country and Global Levels. PLoS Med. 2014;11(9):e1001731.

54. Doorslaer Ev, O’Donnell O, Rannan-Eliya RP, Somanathan A, Adhikari SR, Garg CC, et al. Effect of payments for health care on poverty estimates in 11 countries in Asia: an analysis of household survey data. Lancet. 2006;2006(368):1357-64.

55. Goryakin Y, Suhrcke M. The prevalence and determinants of catastrophic health expenditures attributable to non-communicable diseases in low- and middle-income countries: a methodological commentary. International Journal for Equity in Health. 2014;13(107). doi: 10.1186/s12939-014-0107-1.

56. Moore MA, Shin H-R, Curado M-P, Sobue T. Establishment of an Asian cancer registry network- problems and perspectives. Asian Pacific J Cancer Prev. 2008;9:815-32.

57. Brooks J, Wilson K, Amir Z. Additional financial costs borne by cancer patients: A narrative review Euopean Journal of Oncology Nursing. 2011;15(4):302-10. doi: <https://doi-org.proxy1-bib.sdu.dk/10.1016/j.ejon.2010.10.005>.

58. Longo CJ, Fitch M, Deber RB, Williams AP. Financial and family burden associated with treatment in Ontario, Canada. Supportive Care in Cancer. 2006;14:1077-85.

59. Lee JT, Hamid F, Pati S, Atun R, Millett C. Impact of Noncommunicable Disease Multimorbidity on Healthcare Utilisation and Out-Of-Pocket Expenditures in Middle-Income Countries: Cross Sectional Analysis. PLoS ONE [Electronic Resource]. 10(7):e0127199. PubMed PMID: 26154083.

60. Whitehead M, Dahlgren G, Evans T. Equity and health sector reforms: can low-income countries escape the medical poverty trap? Lancet. 2001;358:833-6.

61. Hamid F, Pati S, Atun R, Millett C. Impact of noncommunicable disease multimorbidity on healthcare utilisation and out-of-pocket expenditures in middle-income countries: Cross sectional analysis. PLoS ONE. 2015;10 (7) (no pagination)(e0127199).

62. Leive A, Xu K. Coping with out-of-pocket health payments: empirical evidence from 15 African countries. Bulletin of the World Health Organization. 2008;86(11).

63. Uddin MJ, Alam N, Koehlmoos TP, Sarma H, Chowdhury MA, Alam DS, et al. Consequences of hypertension and chronic obstructive pulmonary disease, healthcare-seeking behaviors of patients, and responses of the health system: a population-based cross-sectional study in Bangladesh.[Erratum appears in BMC Public Health. 2014;14:823 Note: Koehlmoos, Tracey P [added]]. BMC Public Health. 2014;14:547. PubMed PMID: 24888580.

64. Sauerborn R, Adams A, Hien M. Household Strategies to cope with the economic costs of illness Social Science & Medicine. 1996;43(3):291-301.

65. Kruk ME, Goldmann E, Galea S. Borrowing And Selling To Pay For Health Care In Low- And Middle-Income Countries. Health Affairs. 2009;28(4):1056-66.

66. Singh CH. The public-private differential in health care and health-care costs in India: The case of inpatients. Journal of Public Health. 2009;17(6):401-7.

67. 2017 [Online news]. Kathmandu: Swasthya Khabar Patrika. Available from: <http://swasthyakhabar.com/news-details/4250/2017-05-02>.

68. Ministry of Health and Population [MOHP]. Nepal Health Sector Strategy 2015-2020. Kathmandu, Nepal Ministry of Health and Population [MOHP], 2015.

69. Rashtriya Swasthiya Bima Yojana India: Ministry of Health and Family Welfare; 2009. Available from: <http://www.rsby.gov.in/about_rsby.aspx>.

70. World Health Organization [WHO]. Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care in Low-Resource Settings. 20 Avenue Appia, 1211 Geneva 27, Switzerland: World Health Organization [WHO].

71. Government of Nepal [GoN] Ministry of Health [MoH]. Package of Essential Non-communicable Diseases [Official website]. Kathmandu, Nepal: PHC Revitalization Division; 2016 [cited 2017 18 May]. Available from: <http://www.phcrd.gov.np/index.php/programs/package-essential-non-communicable-disease>.

72. Wagstaff A, Flores G, Hsu J, Smitz M-F, Chepynoga K, Buisman LR, et al. Progress on catastrophic health spending in 133 countries: a retrospective observational study. The Lancet Global Health. 2017;6(2):e169 - e79. doi: <http://dx.doi.org/10.1016/S2214-109X(17)30429-1>.

73. Wagstaff A, Flores G, Smitz M-F, Hsu J, Chepynoga K, Eozenou P. Progress on impoverishing health spending in 122 countries: a retrospective observational study. The Lancet Global Health. 2017;6(2):e180 - e92. doi: <http://dx.doi.org/10.1016/S2214-109X(17)30486-2>.

74. Wells GA, Shea B, O'connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital research Institute, 2011.

75. Taylor AM, Taylor MP. The Purchasing Power Parity Debate. Journal of Economic Perspectives. 2004;18(4):135-58.

**Table 1: Characteristics of the studies**

ind: individual, hld: household, yrs: Years, NA:Not Available

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study Design** | **Location** | **Period of Surveillance** | **Sampling** | **Number in analysis** | **Gender** | **Age** | **Reported NCD** | **Source, Publication year** |
| **Cohort** | India | Apr 2009-Oct 2011 | Purposive | 189 ind | Both | 18 yrs and above | Stroke | Kwatra et al, 2013 [36] |
| Mar 2013-Jul 2014 | Purposive | 644 ind | Both | 0 to 18 | Congenital Heart Disease | Raj et al, 2015 [37] |
| Jun 2011-May2012 | Purposive | 1635 ind | Both | 18 yrs and above | Acute Coronary events | Jan et al, 2016 [35] |
| **Cross- sectional** | India | 1995-96 and 2004 | Random | 200000 hld | NA | NA | Diabetes, Heart Disease, Cancer, Bronchial Asthma | Engelgau et al., 2012[25] |
| 2004 | Random | 74 000 hld | NA | All ages | Cardiovascular disease | Karan et al, 2014 [28] |
| Jun-Sep 2008 | Random | 210 ind | Both | 25-70 yrs | Acute Coronary syndrome | Davidanam et al, 2012[42] |
| 2008–2009 | Random | 500 ind | Both | 25–70 yrs | Cardiovascular disease | Huffman et al, 2011[44] |
| Jan and Jun2004 | Random | Diabetes: 438,  CVD: 2129 ind | Both | NA | Diabetes, Cardiovascular disease | Roa et al , 2011 [38] |
| NR | Purposive | 50 ind | Both | 20-50 yrs | Diabetes | Grover et al, 2005 [46] |
| NR | Purposive | 596 ind | Both | NA | Diabetes | Shobhana et al, 2000 [45] |
| 2004 | Random | 73000 hld | Both | NA | Cancer, Cardiovascular disease, Diabetes | Joe et al, 2015 [33] |
| 2004 | Random | 74000 hld | NA | All ages | Cancer | Mahal et al,2013 [29] |
| NA | Random | 199 ind | Both | NA | Stroke | Das et al, 2010 [39] |
| Mar –May 2011 | Random | 508 ind | Both | NA | Cancer | Nair et al, 2013 [48] |
| Bangladesh | 2012-2013 | Random | 476 ind | Both | ≥ 20 yrs | COPD | Uddin et.al,2014[63] |
| Feb-Apr 2010 | Purposive | 166 ind | Both | 18+ yrs | Diabetes | Joshi et. al, 2012[40] |
| 2009 | Purposive | 3941 hld | NA | NA | Diabetes, Heart Disease, Cancer, Asthma | Hamid et al, 2014 [26] |
| Aug-Nov 2011 | Random | 1593 hld | NA | NA | Heart Disease, Asthma | Rahman et al, 2013 [30] |
| Pakistan | 2009-2010 | Purposive | 67 ind | Female | NA | Breast Cancer | Zaidi et al, 2012 [41] |
| Jul to Sep 2006 | Random | 345 ind | Both | 20-60 yrs | Diabetes | Khowaja et al, 2007 [47] |
| Nepal | Nov 2011- Jan 2012 | Random | 1997 hld | NA | NA | Diabetes, Asthma, Heart Disease | Saito et. al, 2014[31] |
| Nepal, Srilanka, Bangladesh, India | 2002-2003 | Random | Ban:5942, Ind:10692, Nep:882, SriL:6805 hld | NA | 18+ yrs | Angina | Alam et al, 2014 [24] |

**Table 2: Economic Impact of Cardiovascular disease among households in South Asia**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study Design** | **Location** | **Type of Outcome** | **Outcome Specified as** | **Assessment Type** | **Point Estimate** | **Author** |
| **Cohort** | India | OOPP | Per patient cost of hospitalizations due to ST elevated MI | Mean, $ | 2500 | Jan[35] |
| Catastrophic Expenditure | OOPP at 6 week> 30% of annual baseline household income, among insured patient | Percentage | 20 |  |
|  | OOPP at 6 week> 30% of annual baseline household income, among uninsured patient | Percentage | 60 |  |
| OOPP | Total hospital cost (Direct medical+ direct non-medical + indirect costs), at 6 months | Mean, $ (95% CI) | 4962.31 (4467.51, 5452.44) | Kwatra[36] |
|  | Direct medical cost, at 6 months | Mean, $ (95% CI) | 3235.18 (2912.86, 3589.57) |  |
|  | Non-medical cost, at 6 months | Mean, $ (95% CI) | 297.08 (253.74, 342.94) |  |
|  | Indirect cost, at 6 months | Mean, $ (95% CI) | 1429.99 (1231.59, 1648.21) |  |
| OOPP | Total hospitalization cost (Direct+ Indirect costs), for surgery | Mean, $ (95% CI) | 11989 (969-15804) | Raj[37] |
|  | Direct hospital cost | Mean, $ (95% CI) | 10639 (8721-13871) |  |
|  | Indirect hospital cost | Mean, $ (95% CI) | 1119 (696-1728) |  |
| Coping strategy | Borrowing money from friends or relatives, for surgery | Percentage | 49.8 |  |
|  | Pledging gold, for surgery | Percentage | 34 |  |
|  | Private Loans | Percentage | 10.4 |  |
|  | Borrowing money, after hospital discharge (6 months) for covering expenses and loan repayment | Percentage | 52.1 |  |
| **Cross-sectional** | India | Financial Hardship | Financial position not at all adequate to look after patient | Percentage | 22 | Das[39] |
|  | Financial situation very much worsened since patient's illness | Percentage | 44 |  |
| OOPP | Total expenditure (Direct +Indirect costs), for ACS treatment | Median, (Min-Max) | 7620.95 (818.45-57875.92) | Daivadanam[42] |
| Catastrophic Expenditure | Health spending >threshold 40% of household's Capacity to pay | Percentage (95% CI) | 84 (79.04, 88.96) |  |
| Coping strategy | New loans/asset sale vs no loan/asset sale only for ACS treatment | OR (95% CI) | 6.97 (1.48,32.85) |  |
|  | Exclusively used savings | Percentage | 14 |  |
|  | Solely Loans | Percentage | 41 |  |
|  | Combinations of loans, savings, gifts, insurance | Percentage | 37 |  |
| OOPP | Per hospital stay, private + public (1995-1996) | Mean, $ | 1174.81 | Engelgau[25] |
|  | Per hospital stay, private + public 2004 | Mean, $ | 1958.02 |  |
|  | Per outpatient visit, private+public (1995-1996) | Mean, $ | 55.47 |  |
|  | Per outpatient visit, private+public 2004 | Mean, $ | 54.82 |  |
| Catastrophic Expenditure | Patient with CVD vs CDs | OR | 1.12(0.99,1.27) |  |
| Impoverishment | Patient with CVD vs CDs | OR | 1.37(1.23,1.53) |  |
| OOPP | OOPP spending as proportion of total household spending, in high income group | Percentage | 39.3 | Huffman[44] |
|  |  | Total expenditure(direct+indirect), among high income group | Mean, $ (95% CI) | 2916.8 (1056, 5902) |  |
|  | Financial Hardship | Decrease in individual income in high income group | Percentage | 25.1 |  |
|  |  | Decrease in household income in high income group | Percentage | 26.3 |  |
|  | Catastrophic Expenditure | OOP health spending >40% non-food expenditure in low income group | Percentage | 92 |  |
|  |  | ACS vs stroke | OR (95% CI) | 0.6 (0.37, 0.97) |  |
|  |  | CHE among low income group vs high income group | OR (95% CI) | 6.59 (2,23, 19,45) |  |
|  | Distress Financing | Distress financing following CVD related hospitalization in low income group | Percentage | 64 |  |
|  |  | ACS (ref)vs stroke | OR (95% CI) | 1.3 (0.21,0.51) |  |
|  |  | Distress financing among low income group vs high income group | OR (95% CI) | 1.3 (0.68,2.49) |  |
| **Cross-sectional** |  | Distress Financing | Borrowings to meet OOPP for inpatient care (Rural/Urban) | Percentage | 52/25 | Joe[33] |
|  | Contributions/assistance from friends/relatives to meet OOPP for inpatient care (Rural/Urban) | Percentage | 27/18 |  |
|  | Sale assets to meet OOPP for inpatient care (Rural/Urban) | Percentage | 8/5 |  |
|  | CVD vs no CVD for Borrowing to meet OOPP for inpatient care | OR (95% CI) | 0.87 (0.87,0.88) |  |
|  | CVD vs no CVD for Sale of asset to meet OOPP for inpatient care | OR (95% CI) | 1.05 (1.04,1.06) |  |
|  | CVD vs no CVD for Contribution/assistance from friend to meet OOPP for inpatient care | OR (95% CI) | 1.12 (1.11,1.12) |  |
| OOPP | Hospital admissions per household member, in affected households (1yr) | Mean, $ (95% CI) | 252.61 (259.08, 337.43) | Karan[28] |
|  | Hospital admissions per household member, in match control households (1yr) | Mean, $ (95% CI) | 63.21 (52.81, 73.62) |  |
|  | Outpatient visits per household member, in affected households (15 days) | Mean, $ (95% CI) | 9.22 (8.31, 10.13) |  |
|  | Outpatient visits per household member, in match control households (15 days) | Mean, $ (95% CI) | 3.99 (3.23, 5.76) |  |
|  | OOPP spending as proportion of total household spending, in affected household (15 days) | Percentage (95% CI) | 27.22 (25.11, 29.33) |  |
|  | OOPP spending as proportion of total household spending, in match control households (15 days) | Percentage (95% CI) | 10.72 (9.47, 11.97) |  |
| Coping strategy | Borrowed or sold assets to pay for inpatient treatment, in affected household | Percentage (95% CI) | 32.6 (30.74,34.59) |  |
|  | Borrowed or sold assets to pay for inpatient treatment, in matched control household | Percentage (95% CI) | 12.8 (11.41,14.20) |  |
| OOPP | Per hospital stay | Mean, $ | 869.96 | Rao[38] |
|  | Household consumption expenditure, per year | Percentage | 30 |  |
| Coping Strategy | Used household savings for hospital treatment | Percentage | 57 |  |
|  | Borrowed for hospital treatment | Percentage | 35 |  |
|  | Selling of assets for hospital treatment | Percentage | 8 |  |
| Bangladesh | Impoverishment | Headcount impoverishment impact of OOPP | Percentage | 5.88 | Hamid[26] |
|  | Average poverty gap | Mean, $ | 0.018 |  |
|  | Normalized poverty gap | Percentage | 2 |  |
| Distress Financing | Household with Heart Disease vs no Heart Disease | RR (95% CI) | 1.22 (1.05–1.42) | Rahman[30] |
| Nepal | Catastrophic Expenditure | Health care spending >10% of total household expenditure | Concentration Index (95% CI) | −0.247 (−0.497,0.002) | Saito[31] |
|  | Mean Positive Overshoot (Mean level/Additional payments exceeding >10% threshold of THE) | Percentage | 8.3 |  |
|  | HD vs no HD, among household from poorest quintile | RR (95% CI) | 2.24 (1.29, 3.88) |  |
|  | HD vs no HD, among household from wealthiest quintile | RR (95% CI) | 2.36 (0.83, 6.71) |  |
|  |  | OOPP | Hospitalization expenses per person, in angina treated household (4 weeks) | Mean, $ (95% CI) | 0.97 (-0.01, 1.96) | Alam[24] |
| Bangladesh |  | Hospitalization expenses per person, in matched control household (4 weeks) | Mean, $ (95% CI) | 0.24 (0.04, 0.45) |  |
| Catastrophic Expenditure | OOP health spending share of household’s ‘capacity to pay’ at 40% cut-off, in treated household | Percentage (95% CI) | 39.4 (35.87, 42.93) |  |
|  | OOP health spending share of household’s ‘capacity to pay’ at 40% cut-off, in matched control household | Percentage (95% CI) | 35.87 (32.11,39.63) |  |
| Impoverishment | Impoverishment due to OOP health payments, in treated household | Percentage (95% CI) | 12.63 (10.23, 15.03) |  |
|  | Impoverishment due to OOP health payments, in matched control household | Percentage (95% CI) | 11.82 (9.29, 14.35) |  |
| Coping strategy | Borrowing or selling assets to finance health expenditure, in treated household | Percentage (95% CI) | 46.06 (42.46, 49.66) |  |
|  | Borrowing or selling assets to finance health expenditure, in matched control household | Percentage (95% CI) | 40.08 (36.23,43.93) |  |
| India | OOPP | Hospitalization expenses per person, in angina treated household (4 weeks) | Mean, $ (95% CI) | 1.46 (0.88, 2.04) |  |
|  | Hospitalization expenses per person, in matched control household (4 weeks) | Mean, $ (95% CI) | 1.68 (0.35,3.01) |  |
| Catastrophic Expenditure | OOP health spending share of household’s ‘capacity to pay’ at 40% cut-off, in treated household | Percentage (95% CI) | 33 (30.24, 35.76) |  |
|  | OOP health spending share of household’s ‘capacity to pay’ at 40% cut-off, in matched control household | Percentage (95% CI) | 26.3 (23.38, 29.22) |  |
| Impoverishment | Impoverishment due to OOP health payments, in treated household | Percentage (95% CI) | 10.2 (8.43,11.97) |  |
|  | Impoverishment due to OOP health payments, in matched control household | Percentage (95% CI) | 8.32 (6.49, 10.15) |  |
| Coping strategy | Borrowing or selling assets to finance health expenditure, in treated household | Percentage (95% CI) | 51.79 (48.86, 54.72) |  |
|  | Borrowing or selling assets to finance health expenditure, in matched control household | Percentage (95% CI) | 43.56 (40.27, 46.85) |  |
| Nepal | OOPP | Hospitalization expenses per person, in angina treated household (4 weeks) | Mean, $ (95% CI) | 1.18 (0.15, 2.20) |  |
|  | Hospitalization expenses per person, in matched control household (4 weeks) | Mean, $ (95% CI) | 0.47 (-0.01, 0.94) |  |
| Catastrophic Expenditure | OOP health spending share of household’s ‘capacity to pay’ at 40% cut-off, in treated household | Percentage (95% CI) | 21.27 (17.99, 24.55) |  |
|  | OOPP health spending share of household’s ‘capacity to pay’ at 40% cut-off, in matched control household | Percentage (95% CI) | 16.75 (13.61, 19.89) |  |
| Impoverishment | Impoverishment due to OOP health payments, in treated household | Percentage (95% CI) | 8.37 (6.15, 10.59) |  |
|  | Impoverishment due to OOP health payments, in matched control household | Percentage (95% CI) | 6.2 (4.17, 8.23) |  |
| Coping strategy | Borrowing or selling assets to finance health expenditure, in treated household | Percentage (95% CI) | 57.62 (53.66, 61.58) |  |
|  | Borrowing or selling assets to finance health expenditure, in matched control household | Percentage (95% CI) | 53.6 (49.41, 57.79) |  |
| SriLanka | OOPP | Hospitalization expenses per person, in angina treated household (4 weeks) | Mean, $ (95% CI) | 1.97 (1.48, 2.45) |  |
|  | Hospitalization expenses per person, in matched control household (4 weeks) | Mean, $ (95% CI) | 0.18 (-0.04, 0.41) |  |
| Catastrophic Expenditure | OOP health spending share of household’s ‘capacity to pay’ at 40% cut-off, in treated household | Percentage (95% CI) | 21.87 (17.34, 26.40) |  |
|  | OOPP health spending share of household’s ‘capacity to pay’ at 40% cut-off, in matched control household | Percentage (95% CI) | 11.87 (8, 15.74) |  |
| Impoverishment | Impoverishment due to OOP health payments, in treated household | Percentage (95% CI) | 5.31 (2.85, 7.77) |  |
|  | Impoverishment due to OOP health payments, in matched control household | Percentage (95% CI) | 1.87 (0.25,3.49) |  |
| Coping strategy | Borrowing or selling assets to finance health expenditure, in treated household | Percentage (95% CI) | 21.25 (16.77, 25.73) |  |
|  | Borrowing or selling assets to finance health expenditure, in matched control household | Percentage (95% CI) | 13.44 (9.36,17.52) |  |

OR: Odds Ratio, HD: Heart Disease, THE: Total Health Expenditure, CVD: Cardiovascular Disease, OOP: Out of Pocket, CI: Confidence Interval

**Table 3: Economic Impact of Diabetes**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study Design** | **Location** | **Type of Outcome** | **Outcome Specified as** | **Assessment Type** | **Point Estimate** | **Author** |
| **Cross- sectional** | India | OOPP | Per hospital stay, private + public (1995-1996) | Mean, $ | 456.87 | Engelgau[25] |
|  | Per hospital stay, private + public 2004 | Mean, $ | 783.21 |  |
|  | Per outpatient visit, private+public (1995-1996) | Mean, $ | 24.14 |  |
|  | Per outpatient visit, private+public 2004 | Mean, $ | 41.77 |  |
| OOPP | Direct costs, per year (eg. Drugs, transport, consultations) | Mean, $ (SD) | 1103.30 (948.68) | Grover [46] |
|  | Indirect costs, per year (eg. Loss of income, days lost because of illness for patient and caregivers) | Mean, $ (SD) | 463.57 (1121.87) | |
| Distress Financing | Borrowed to meet OOPP on inpatient care (Rural/Urban) | Percentage | 46/26 | Joe[27] |
|  | Contributions/assistance from friends/relatives to meet OOP expenditure on inpatient care (Rural/Urban) | Percentage | 27/21 |  |
|  | Sale assets to meet OOPP on inpatient care (Rural/Urban) | Percentage | 9/2 |  |
|  | Diabetes vs no diabetes: Borrowing to meet OOPP for inpatient care | OR (95% CI) | 1.01 (1.00,1.01) | |
|  | Diabetes vs no diabetes: Sale of asset to meet OOPP for inpatient care | OR (95% CI) | 1.13 (1.11,1.15) | |
|  | Diabetes vs no diabetes: Contribution/assistance from friend to meet OOPP for inpatient care | OR (95% CI) | 1.21 (1.20,1.22) | |
| OOPP | Mean OOP payment per hospitalization | Mean, $ | 418.49 | Rao[38] |
|  | OPP share of total annual household expenditure | Percentage | 17 |  |
| Income | Family income in private hospital, per year | Mean, $ | 6602.13 | Shobhana[45] |
|  | Family income in public hospital, per year | Mean, $ | 1320.43 |  |
| OOPP | Income spent on DM, by inpatient care | Percentage | 17.5 |  |
|  | Income spent on DM, by outpatient care | Percentage | 7.7 |  |
|  | OOPP | Average cost for each doctor visit | Mean, $ (SD) | 10.83 (6.799) | Joshi [28] |
| Bangladesh | Impoverishment | Headcount impoverishment impact of OOPP | Percentage | 5.25 | Hamid[61] |
|  | Average poverty gap | Mean, $ | 0.011 |  |
|  |  | Normalized poverty gap | Percentage | 1 |  |
| Pakistan | OOPP | Direct cost, per year | Mean, $ | 939.88 | Khowaja[47] |
|  | Indirect cost, per year | Mean, $ | 68.18 |  |
| Nepal | Catastrophic Expenditure | Household spending >10% of total expenditure on health care | Concentration Index (95% CI) | 0.099(-0.304,0.107) | Saito[31] |
|  | Mean Positive Overshoot (Mean level/Additional payments exceeding >10% threshold of THE) | Percentage | 10.2 |  |
|  | Diabetes vs no diabetes, among household from poorest quintile | RR (95% CI) | 2.37 (1.16 ,4.83) | |
|  | Diabetes vs no diabetes, among household from wealthiest quintile | RR (95% CI) | * 1. 0.45, 2.39) | |

DM: Diabetes Mellitus, SD: Standard Deviation, THE: Total Household Expenditure

**Table 4: Economic Impact of Cancer among household in South Asia**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study Design** | **Location** | **Type of Outcome** | **Outcome Specified as** | **Assessment Type** | **Point Estimate** | **Author** |
| **Cross- sectional** | India | OOPP | Per hospital stay, private + public (1995-1996) | Mean, $ | 1044.28 | Engelgau [25] |
|  | Per hospital stay, private + public 2004 | Mean, $ | 2349.62 |  |
|  | Per outpatient visit, private + public (1995-1996) | Mean, $ | 78.32 |  |
|  | Per outpatient visit, private + public (1995-1996) | Mean, $ | 110.95 |  |
| Catastrophic Expenditure | Patients with Cancer versus CDs | OR (95% CI) | 2.7 (2.10, 3.10) |  |
| Impoverishment | Patients with Cancer versus CDs | OR (95% CI) | 2.33 (1.86, 2.91) |  |
| Distress Financing | Borrowed for financing inpatient care (Rural/Urban) | Percentage | 60/37 | Joe[27] |
|  | Contributions/assistance from friends/relatives for financing inpatient care(Rural/Urban) | Percentage | 32/19 |  |
|  | Sale assets for financing inpatient care(Rural/Urban) | Percentage | 14/10 |  |
|  | Cancer vs no cancer: Borrowing for inpatient care | OR (95% CI) | 1.11 (1.10,1.12) |  |
|  | Cancer vs no cancer: Sale of asset for financing inpatient care | OR (95% CI) | 1.33 (1.32,1.34) |  |
|  | Cancer vs no cancer: Contribution from friends/relatives for financing inpatient care | OR (95% CI) | 1.29 (1.28,1.3) |  |
| OOPP | Inpatient OOPE, per member in cancer affected household (1year) | Mean, $ | 326.93 (277.87, 375.99) | Mahal[29] |
|  | Inpatient OOPE, per member in matched control household (1year) | Mean, $ | 66.42 (43.21, 89.69) |  |
|  | Non-medical consumption expenditure, per member in cancer affected household (15days) | Mean, $ (95% CI) | 18.09(18.53, 21.05) |  |
|  | Non-medical consumption expenditure, per member in cancer affected household (15days) | Mean, $ (95% CI) | 19.76 (18.53, 21.05) |  |
| Coping Strategy | Borrowing or selling assets to finance inpatient care in cancer affected household | Percentage (95% CI) | 51.4(47.98, 54.82) |  |
|  | Borrowing or selling assets to finance inpatient care in matched control household | Percentage (95% CI) | 15.77(13.28, 18.26) |  |
| OOPP | Cost of investigation | Mean, $ | 1030.42 | Nair[48] |
|  | Cost of treatment | Mean, $ | 2543.02 |  |
|  | Indirect cost | Mean, $ | 1677.33 |  |
|  | Opportunity cost | Mean, $ | 1118.20 |  |
| Hardship | Faced financial hardship | Percentage | 75 |  |
| Coping Strategy | Family saving | Percentage | 36.5 |  |
|  | Borrowings | Percentage | 39.12 |  |
|  | Sales of assets (land, cattle, ornament, etc.) | Percentage | 12.27 |  |
|  | Medical reimbursement/ health insurance | Percentage | 6.22 |  |
|  | Other assistance (Government/philanthropic) | Percentage | 5.89 |  |
| Bangladesh | Impoverishment | Headcount impoverishment impact of OOPP | Percentage | 25 | Hamid[61] |
|  | Average poverty gap | Mean, $ | 0.068 |  |
|  |  | Normalized poverty gap | Percentage | 8 |  |
| Pakistan | Hardship | Cost more than anticipated | Percentage | 70 | Zaidi[41] |
|  | Perceived level of burden unmanageable | Percentage | 70 |  |

**Table 5: Economic Impact of Chronic respiratory disease among household in South Asia**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study Design** | **Location** | **Type of Outcome** | **Outcome Specified as** | **Assessment Type** | **Point Estimate** | **Author** |
| **Cross-sectional** | India | OOPP | Per hospital stay, private + public (1995-1996) | Mean, $ | 195.80 | Engelgau[25] |
| OOPP | Per hospital stay, private + public 2004 | Mean, $ | 522.13 |  |
|  | Per outpatient visit, private + public (1995-1996) | Mean, $ | 20.88 |  |
|  | Per outpatient visit, private + public 2004 | Mean, $ | 33.93 |  |
| Bangladesh | Impoverishment | Headcount impoverishment impact of OOPP | Percentage | 5.89 | Hamid[61] |
|  | Average poverty gap | Mean, $ | 0.018 |  |
|  | Normalized poverty gap | Percentage | 2 |  |
| Distress Financing | Household with Asthma vs no Asthma | RR (95% CI) | 1.73 (1.35–2.22) | Rahman[30] |
| Financial Hardship | Prevalence of economic consequences (Rural/Urban) | Percentage | 2.4/12.5 | Uddin[63] |
| OOPP | OOPE per visit for seeking outpatient treatment for COPD Urban | Mean, $ | 41.98 |  |
|  | OOPE per visit for seeking outpatient treatment for COPD Rural | Mean, $ | 4.38 |  |
| Coping Strategy | Sold household assets (Rural/Urban) | Percentage | 0.3/1.1 |  |
|  | Spent/reduced savings(Rural/Urban) | Percentage | 0.0/4.3 |  |
|  | Reduced expenditure on food (Rural/Urban) | Percentage | 0.7/6.5 |  |
|  | Borrowed money from relative/friend (Rural/Urban) | Percentage | 1/7.1 |  |
| Nepal | Catastrophic Expenditure | Household spending >10% of total expenditure on health care | Concentration Index (95% CI) | −0.185 (−0.389 to 0.018) | Saito[31] |
|  | Mean Positive Overshoot (Mean level/Additional payments exceeding >10% threshold of THE) | Percentage | 12.3 |  |
|  | Asthma vs no Asthma, among household from poorest quintile | RR (95% CI) | 2.09 (1.28, 3.42) |  |
|  | Asthma vs no Asthma, among household from wealthiest quintile | RR (95% CI) | 1.39 (0.40, 4.82) |  |